Aligos Therapeutics Inc. (NASDAQ:ALGS) shares are trending overnight after the company announced a licensing milestone and regulatory progress for its chronic hepatitis B treatment candidate in China.
Aligos closed Monday’s regular session at $5.85, up 4.65%. Shares continued higher in after-hours trading, gaining 12.48% to $6.58.
Aligos Therapeutics is a clinical-stage biotechnology company developing therapies for liver and viral diseases, including chronic hepatitis B virus infection, MASH, obesity and coronaviruses.
Licensing Payment, China Regulatory Milestone
The after-hours rally followed Aligos’ announcement that it received a $25M upfront payment under its exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, for pevifoscorvir sodium in Greater China.
